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patients with suspected lung cancer. 
Developing a simple, easy-to-perform 
diagnostic blood test for lung cancer 
is ambitious, but a promising develop-
ment in this regard is the identification 
of circulating tumor cells.
Advancements in microfluidic 
technology have led to the development 
of engineering systems that filter 1 ml 
of blood through 900 multiple crescent-
shaped arrays with a pore size of 5μm, 
which allows red cell to pass through, 
and larger white cells sufficiently 
deformable to squeeze through whereas 
large and inflexible cancer cells remain 
trapped.
Using a microfludic system, we 
identified small-cell carcinoma in 1 ml 
of blood of a patient (previously undi-
agnosed with cancer) scheduled to 
undergo diagnostic surgical biopsy. The 
blood was obtained preprocedure, and 
microfluidic hematoxylin and eosin-
staining techniques allowed us to apply 
conventional histological techniques 
and World Health Organization crite-
ria within the chip, and the diagnosis 
was subsequently confirmed on surgi-
cally obtained formalin-fixed paraf-
fin-embedded biopsy specimens. We 
demonstrate proof-of-concept applica-
tion of microfluidic technology to trap 
circulating tumor cells and hypothesize 
that it may be used as a diagnostic blood 
test for cancer.
Lung cancer is the leading cause 
of cancer death worldwide and sur-
vival of patients with lung cancer in the 
United Kingdom remains relentlessly 
among the lowest in Europe; delays in 
diagnosis leading to late presentation is 
an important contributing factor to poor 
outcomes. Confirmatory tissue diagno-
sis of lung cancer is obtained either by 
computed tomography–guided biopsy, 
endobronchial biopsy (or cytology), 
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To the Editor:
In the August 2012 issue of 
Journal of Thoracic Oncology, we were 
encouraged to analyze the processes 
in care for non–small-cell lung can-
cer patients to narrow the gap between 
desired and actual performance.1 In this 
letter I would like to affirm the impor-
tance of selecting valid quality indicators 
(QI) that are internationally applicable.
Quality indicators may assess a 
care pathway’s structure (i.e., waiting 
times), process (i.e., mediastinal stag-
ing rates), patient–orientation (i.e., 
side-effect awareness rates) and out-
come (i.e., morbidity, mortality). The 
valiity of the QI lies in the data qual-
ity and an evidence-based link between 
indicator, clinical outcome, and recog-
nized guidelines.1–4
Quality indicators must be able 
to identify room for improvement, have 
wide patient applicability, and be sen-
sitive to differences in quality of care.3 
QIs have been used in evaluating pro-
cesses of care during pulmonary resec-
tion; however, the selection process 
often hinges on the consensus of ad hoc 
specialist groups.5 This highlights the 
youthful stage of quality metrics in lung 
cancer management. However, not all 
indicators provide utility, and a more rig-
orous approach will elevate such studies 
from self-affirming audits to productive 
Quality Improvement Programs.
The Danish experience of reduced 
30-day surgical mortality (5.2%–3.6%), 
time to surgery (69%– 87% within 14 
days) and 1- to 2-year survival (1 year: 
69% up to 77%, 2 years: 50% up to 
60%) provides heartening evidence of 
the utility of valid QIs in non–small-cell 
lung cancer care.2
The greatest strength of all 
Quality Improvement initiatives is in 
maintaining review and refinement. The 
multidisciplinary meeting format has 
been the big change most people car-
ing for lung cancer patients have expe-
rienced, yet more is needed to achieve 
consistently high standards of care. The 
proposed use of a valid Quality Indicator 
dashboard to drive ongoing review has 
the exciting potential to exceed benefits 
of current therapeutic advances.1
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